Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial
- 1Anagenix IP Ltd
Abstract
BackgroundPrediabetes is an intermediate state of increased glucose concentrations above the normal range but below the diagnostic threshold for type 2 diabetes (T2D). Adults with overweight and prediabetes are at increased risk of progression to T2D and metabolic imbalance. Feiolix(R) -a whole-fruit feijoa powder rich in abscisic acid, polyphenols and dietary fibre which may support metabolic health through multiple, potentially complementary pathways.
ObjectiveTo evaluate the effects of low and high-dose Feiolix compared with placebo, on HbA1C, glucagon like peptide (GLP-1) and other metabolic parameters
MethodsAdults aged 21-65 years with prediabetes i.e. glycosylated hemoglobulin (HbA1c) 5.7-6.4% and overweight with body mass index (BMI)- 25.0-29.9 kg/m{superscript 2} were randomised to receive Feiolix-LD (300 mg/day) or Feiolix-HD (1,150 mg/day), or placebo (maltodextrin) for 12 weeks. Anthropometric measurements were obtained monthly, and fasting blood samples were collected at baseline and 12 weeks post intervention. Postprandial blood samples were collected at baseline and 12 weeks. Outcomes included HbA1c, GLP-1, fasting plasma glucose, insulin resistance lipid markers, body weight and BMI. Analyses were conducted using ANCOVA model with baseline values as covariates.
ResultOf 41 individuals screened, 39 were randomised (13 per group); one participant withdrew from the Feiolix-LD. At week 12, HbA1c decreased by 0.5% in the Feiolix-HD and by 0.4% in the Feiolix-LD, with both reductions significantly greater than placebo (p < 0.05); Compared with placebo, Feiolix supplementation significantly lowered fasting plasma glucose, insulin, HOMA-IR, total cholesterol and LDL-cholesterol. The Feiolix-HD attenuated the increase in triglycerides and reduced body weight and BMI by month 2 compared to placebo. GLP-1 concentrations did not differ between groups. However, no change in GLP-1 was observed between the treatments. No treatment-related adverse events were reported.
ConclusionThis study supports the potential of Feiolix supplementation to improve metabolic health, including glycemic and lipid outcomes, with additional benefits for body weight and BMI at the higher dose.
Related
- Effects of Kinect-based mixed-reality exercise and deep-sea water consumption on metabolic syndrome: a randomized controlled trial
- “A better system” – managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care
- Effects of Whole “Navelina” Orange Consumption on Glucose Homeostasis and Fructosamine Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial
- Mercury exposure during pregnancy and the effect of harmonised fish-consumption advice: results from the multi-country randomised HBM4EU-MOM study
- A latent profile analysis of attitudes towards artificial sweetener consumption among adults in Saudi Arabia
BibTeX
@misc{shrestha2026effect,
title = {{Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial}},
author = {A. Shrestha and A. Sarvate and D. Mehta and N. Nargundhar and D. Deshmukh and C. Godse},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.13.26362958},
url = {https://www.medrxiv.org/content/10.64898/2026.09.13.26362958v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial
AU - A. Shrestha
AU - A. Sarvate
AU - D. Mehta
AU - N. Nargundhar
AU - D. Deshmukh
AU - C. Godse
PY - 2026
DA - 2026/09/13
PB - medRxiv
DO - 10.64898/2026.09.13.26362958
UR - https://www.medrxiv.org/content/10.64898/2026.09.13.26362958v1
AB - BackgroundPrediabetes is an intermediate state of increased glucose concentrations above the normal range but below the diagnostic threshold for type 2 diabetes (T2D). Adults with overweight and prediabetes are at increased risk of progression to T2D and metabolic imbalance. Feiolix(R) -a whole-fruit feijoa powder rich in abscisic acid, polyphenols and dietary fibre which may support metabolic health through multiple, potentially complementary pathways. ObjectiveTo evaluate the effects of low and high-dose Feiolix compared with placebo, on HbA1C, glucagon like peptide (GLP-1) and other metabolic parameters MethodsAdults aged 21-65 years with prediabetes i.e. glycosylated hemoglobulin (HbA1c) 5.7-6.4% and overweight with body mass index (BMI)- 25.0-29.9 kg/m{superscript 2} were randomised to receive Feiolix-LD (300 mg/day) or Feiolix-HD (1,150 mg/day), or placebo (maltodextrin) for 12 weeks. Anthropometric measurements were obtained monthly, and fasting blood samples were collected at baseline and 12 weeks post intervention. Postprandial blood samples were collected at baseline and 12 weeks. Outcomes included HbA1c, GLP-1, fasting plasma glucose, insulin resistance lipid markers, body weight and BMI. Analyses were conducted using ANCOVA model with baseline values as covariates. ResultOf 41 individuals screened, 39 were randomised (13 per group); one participant withdrew from the Feiolix-LD. At week 12, HbA1c decreased by 0.5% in the Feiolix-HD and by 0.4% in the Feiolix-LD, with both reductions significantly greater than placebo (p < 0.05); Compared with placebo, Feiolix supplementation significantly lowered fasting plasma glucose, insulin, HOMA-IR, total cholesterol and LDL-cholesterol. The Feiolix-HD attenuated the increase in triglycerides and reduced body weight and BMI by month 2 compared to placebo. GLP-1 concentrations did not differ between groups. However, no change in GLP-1 was observed between the treatments. No treatment-related adverse events were reported. ConclusionThis study supports the potential of Feiolix supplementation to improve metabolic health, including glycemic and lipid outcomes, with additional benefits for body weight and BMI at the higher dose.
ER -